Adaptive Biotechnologies Corporation (ADPT)

2,6000 -0,0100 (-0,38%) Alla chiusura: 04:00PM EDT

Adaptive Biotechnologies Corporation

1165 Eastlake Avenue East
Seattle, WA 98109
United States
206 659 0067
https://www.adaptivebiotech.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 709

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Chad M. Robins M.B.A.	Co-Founder, CEO & Chairman	1,19M	248,74k	1974
Ms. Julie Rubinstein	President & COO	760,46k	N/D	1972
Dr. Harlan S. Robins Ph.D.	Co-Founder & Chief Scientific Officer	759,61k	N/D	1973
Mr. Kyle Piskel	VP, CFO & Principal Accounting Officer	375,9k	N/D	1984
Dr. Sharon Benzeno Ph.D.	Chief Commercial Officer of Immune Medicine	671,29k	N/D	1974
Mr. Christopher Carlson Ph.D.	Founder	N/D	N/D	N/D
Karina Calzadilla	Vice President of Investor Relations	N/D	N/D	N/D
Ms. Stacy L. Taylor	Senior VP, General Counsel & Corporate Secretary	N/D	N/D	1960
Mr. Francis T. Lo	Chief People Officer	N/D	N/D	1981
Ms. Susan Bobulsky	Chief Commercial Officer of MRD	N/D	N/D	1982

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Governance aziendale

L'ISS Governance QualityScore di Adaptive Biotechnologies Corporation al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.